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Abstract. Purpose: This study was performed to investi-
gate the value of 18F-fluorodeoxyglucose positron emission
tomography ([18F]FDG-PET) in the diagnosis of large-
vessel vasculitis and the assessment of activity and extent
of disease.
Methods: Twenty-six consecutive patients (21 females, 5
males; median age – years, range 17–86 years) with giant
cell arteritis or Takayasu’s arteritis were examined with
[18F]FDG-PET. Follow-up scans were performed in four
patients. Twenty-six age- and gender-matched controls
(21 females, 5males;median age 71 years, range 17–86 years)
were included. The severity of large-vessel [18F]FDG up-
take was visually graded using a four-point scale. C-reac-
tive protein (CRP) and the erythrocyte sedimentation rate
(ESR) were measured and correlated with [18F]FDG-PET
results by logistic regression.
Results: [18F]FDG-PET revealed pathological findings in
18 of 26 patients. Three scans were categorised as grade I,
12 as grade II and 3 as grade III arteritis. Visual grade was
significantly correlated with both CRP and ESR levels
(p=0.002 and 0.007 respectively; grade I: CRP 4.0 mg/l,
ESR 6 mm/h; grade II: CRP 37 mg/l, ESR 46 mm/h; grade
III: CRP 172 mg/l, ESR 90 mm/h). Overall sensitivity was
60% (95% CI 40.6–77.3%), specificity 99.8% (95% CI
89.1–100%), positive predictive value 99.7% (95%CI 77–
100%), negative predictive value 67.9% (95% CI 49.8–
80.9%) and accuracy 78.6% (95% CI 65.6–88.4%). In
patients presenting with a CRP <12 mg/l or an ESR
<12 mm/h, logistic regression revealed a sensitivity of less
than 50%. In patients with high CRP/ESR levels,
sensitivity was 95.5%/80.7%.
Conclusion: [18F]FDG-PET is highly effective in assess-
ing the activity and the extent of large-vessel vasculitis.
Visual grading was validated as representing the severity
of inflammation. Its use is simple and provides high
specificity, while high sensitivity is achieved by scanning
in the state of active inflammation.
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Introduction
The diagnosis of large-vessel vasculitis and the assessment
of its activity and extent remain challenging, especially in
patients presenting with a constellation of non-specific
symptoms and laboratory tests. The standard diagnostic pro-
cedures include biopsy, angiography, ultrasound and mag-
netic resonance angiography (MRA); nevertheless, these
procedures are invasive, are largely operator-dependent or
document only morphological changes, such as stenosis,
occlusion and aneurysmal transformation, which mainly
occur in late stages of the disease [1–5].
Positron emission tomography (PET) is an operator-
independent, non-invasive metabolic imaging modality
based on the regional distribution of 18F-fluorodeoxyglucose
([18F]FDG) which plays a major role in the management of
oncology patients. However, activated inflammatory cells
have also been shown to overexpress glucose transport-
ers and to accumulate increased amounts of glucose and
structurally related substances such as [18F]FDG [6, 7];
therefore, [18F]FDG-PET may become a useful tool in the
evaluation ofTakayasu’s arteritis (TA) andgiant cell arteritis
(GCA). Nevertheless, the lack of accurate criteria for
vasculitis imaging based on [18F]FDG-PET has restricted
its use so far. This study therefore aimed to explore the
properties of [18F]FDG-PET in the detection of large-ves-
sel vasculitis and in the assessment of the activity and ex-
tent of disease.
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Materials and methods
Patients
Throughout a period of 24 months (from April 2002 to April 2004),
26 consecutive patients (21 females, 5 males; median age 71 years,
range 17–86 years) with a clinical diagnosis of GCA (20 patients) or
TA (six patients) were examined with [18F]FDG-PET. Follow-up
scans were performed in four patients. Twenty-one of the 30 scans
(70%) were performed under simultaneous glucocorticosteroid
treatment. The classification as GCA or TA was made according to
the ACR classification criteria [8, 9] and verified when at least three
of the criteria were present. Patients were referred by the Department
of Rheumatology of the University Medical Centre. Patient charac-
teristics and baseline investigation results are shown in Table 1.
Additionally, in order to determine normal values for vascular
uptake on [18F]FDG-PET, an age- and gender-matched reference group
of 26 patients (21 females, 5 males; median age 71 years, range 17–
86 years) who underwent [18F]FDG-PET for malignancy were visu-
ally scored.
Biochemical investigations
The serum levels of CRP (Tina-Quant, Roche, Switzerland; reference
range <10 mg/l), haemoglobin (ADVIA 120, Bayer, Switzerland; ref-
erence range 120–160 g/l), leucocytes (ADVIA 120; reference range
3.5–10×109 l−1) and thrombocytes (ADVIA 120; reference range 150–
450×109 l−1) and the erythrocyte sedimentation rate (Westergren
method) were measured in the week of the [18F]FDG-PET scan to
assess the severity of systemic inflammation.
PET acquisition
[18F]FDG-PETwas performed after patients had fasted for 12 h using
a dedicated full-ring PET camera system (ECAT EXACT-922/47,
Siemens, Germany) with 32 rings and an axial field of view of
16 cm. The serum glucose level was measured before [18F]FDG
administration in all patients and was below 180 mg/dl (Glucometer
Elite, Bayer Diagnostics, UK). Acquisition was started 45 min after
intravenous injection of 5 MBq/kg body weight of [18F]FDG with
the patient in the supine position. We performed whole-body scans
using 2D acquisition with 12–14 contiguous bed positions (8 min/bed
position: 6-min emission scan and 2-min attenuation correction with a
rotating 68Ge line sources). Iterative reconstruction of the transaxial
slices was performed using the ordered subset–expectation maxi-
misation (OS-EM) algorithm (two iterations, eight subsets).
Evaluation and scoring of data
Images were judged by two experienced nuclear medicine physi-
cians blinded to the clinical and laboratory data. At a time interval of
1 month, the same two observers evaluated the same images blinded
to the previous judgment. The severity of large-vessel [18F]FDG up-
take was visually graded using a four-point scale (Fig. 1a): 0, no
uptake present; I, low-grade uptake (uptake present but lower than
liver uptake); II, intermediate-grade uptake (similar to liver uptake);
III, high-grade uptake (uptake higher than liver uptake).
Statistical evaluation
All data are expressed as median (range) in text and tables. To as-
certain whether CRP and ESR levels were positively associated with
the grade of [18F]FDG uptake, the Jonckheere-Terpstra test was
used. Logistic regression was used to assess the effects of CRP and
ESR on the sensitivity of [18F]FDG-PET. Statistical significance
was defined as p<0.05. Data were analysed using Statistica Version
6.0 for Windows (StatSoft Inc., Tulsa, USA).
Results
Reference group
Grade I [18F]FDG uptake was present in the ascending
aorta in 20/26 (77%) patients, in the aortic arch in 17/26
(65%) and in the thoracic part of the descending aorta in
4/26 (15%). Visible [18F]FDG uptake in the abdominal part
of the descending aorta or in one of the large aortic branches
was not found in any of the control group, nor were there
any instances of grade II or III uptake in controls. There-
fore, in the present study, grade II or III uptake in the
thoracic aorta and any visible uptake in other segments was
considered as pathological and due to active arterial
inflammation.
Assessment of activity
Thirty PET scans were performed (26 baseline and 4 fol-
low-up studies) in the patients. Three scans were judged as
grade I, 12 as grade II and 3 as grade III arteritis. Inter-
Table 1. Patient characteristics and baseline investigation results
All
patients
(n=26)
Giant cell
arteritis
(n=20)
Takayasu’s
arteritis
(n=6)
Females/males 21/5 15/5 6/0
Age (years) 71
(17–86)
72
(53–86)
40
(17–74)
Duration of
disease (year)
1.0
(0.1–24.4)
1.0
(0.1–3.8)
2.9
(0.4–24.4)
Pre-PET lab results
ESR (mm/h) 35
(4–130)
43
(4–130)
18
(5–75)
CRP (mg/l) 27.4
(0.3–220)
32.5
(1.8–220)
3
(0.3–29)
Haemoglobin
(mg/dl)
13.1
(8.1–14.8)
11.8
(8.1–14.8)
13.1
(8.6–13.6)
Leucocytes
(×109 l−1)
7.8
(5.1–17.4)
9.6
(6.3–17.4)
7.1
(5.1–7.5)
Thrombocytes
(×109 l−1)
369
(142–686)
409
(142–686)
279
(235–415)
Values are expressed as median (range). The reference ranges for
the laboratory values are: CRP <10 mg/l, haemoglobin 120–160 g/l,
leucocytes 3.5–10.00×109 l−1, thrombocytes 150–450×109 l−1
ESR erythrocyte sedimentation rate, CRP C-reactive protein
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observer agreement regarding the severity score was
obtained in 93.3% (28/30) of the scans, and the intra-
observer reproducibility was 90% (27/30). The visual grade
and the patient’s ESRwere significantly correlated: patients
with grade I arteritis had an ESR of 6 mm/h (4–9 mm/h),
patients with grade II arteritis had an ESR of 46 mm/h (6–
130 mm/h) and patients with grade III arteritis showed an
ESR of 90 mm/h (72–100 mm/h) (p=0.007; Fig. 2a). We
also found a significant correlation between the visual
grade and the patient’s CRP: patients with grade I arteritis
had a mean CRP of 4.0 mg/l (2–10 mg/l), grade II patients
had a CRP of 37 mg/l (2–158 mg/l) and patients with
grade III arteritis showed a CRP of 172 mg/l (95–220 mg/l)
(p=0.002; Fig. 2b).
Follow-up PET studies were performed in four patients.
All of them had received glucocorticosteroid drug treat-
Fig. 2. Correlation of large-vessel [18F]FDG uptake with ESR and CRP level. Based on the Jonckheere-Terpstra test, the grade of large-
vessel [18F]FDG uptake (grade I–III) was positively correlated with both ESR (a, p=0.007) and CRP level (b, p=0.002)
Fig. 1. a Examples of visual grading of
[18F]FDG uptake. b Non-pathological
whole-body [18F]FDG-PET scan. c Whole-
body [18F]FDG-PET scan showing extensive
large-vessel arteritis
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ment after the baseline study, resulting in clinical improve-
ment and mean decreases of 31 mm/h in the ESR and
38 mg/l in CRP. Follow-up [18F]FDG-PET confirmed a
marked reduction in disease activity (from grade II to I in
three patients and from grade II to 0 in one patient) and
extension (the number of affected segments in the four
patients decreased from 28 in the baseline study to 15 in the
follow-up study).
Assessment of diagnosis
In the study group, 18/30 scans showed pathological
large-vessel [18F]FDG uptake, while in the control group
0/26 scans were found to be pathological due to active arte-
rial inflammation. Statistical analysis revealed an overall
sensitivity of 60% (95% CI 40.6–77.3%), a specificity of
99.8% (95%CI 89.1–100%), a positive predictive value of
99.7% (95% CI 77–100%), a negative predictive value
of 67.9% (95% CI 49.8–80.9%) and an accuracy of 78.6%
(95% CI 65.6–88.4%). Non-pathological [18F]FDG uptake
(grade I uptake in the thoracic part of the aorta) was found in
2/30 studies, and 10/30 studies showed no visible [18F]FDG
uptake. Overall, abnormal [18F]FDG uptake was present in
129/360 (35.8%) vascular regions studied (Table 2). For
patients presenting with an ESR <12 mm/h, logistic re-
gression revealed a sensitivity of less than 50%. In patients
with a high ESR, sensitivity increased to 80.7% (Fig. 3).
Separate analysis in those with a high ESR revealed a
sensitivity of 78.6% for patients suffering from GCA (22
scans) and 40.3% for patients suffering from TA (eight
scans).
Compared with ESR, CRP showed a superior correla-
tion with the sensitivity of [18F]FDG-PET. For patients
presenting with a CRP <12 mg/l, logistic regression re-
vealed [18F]FDG-PET to have a sensitivity of less than
50%. With high CRP levels, sensitivity increased to 95.5%
(Fig. 3). Separate analysis revealed a sensitivity of 93.7%
for patients suffering from GCA (22 scans) and 46.6% for
patients suffering from TA (eight scans), at high CRP
levels.
Ten of 21 PET scans (47.6%) with and eight of nine
scans (88.9%) without simultaneous glucocorticosteroid
treatment showed pathological large-vessel [18F]FDG up-
take (p=0.034).
Assessment of disease extent
The extent of large-vessel vasculitis was assessed using
MRA, ultrasound, temporal artery biopsy or aortic biopsy
prior to [18F]FDG-PET. Thereby, 6/26 patients (23.1%)
were diagnosed as having extensive inflammation (with
involvement of the aorta and major aortic branches) while
20/26 (76.9%) were considered to have limited inflamma-
tion (involvement of the aorta without involvement of ma-
jor aortic branches). [18F]FDG-PETconfirmed the diagnosis
of extensive disease in all six of the aforementioned patients
(100%), revealing a median of 10 (5–13) affected vascular
segments in this group. PETalso confirmed the diagnosis of
limited disease in 12/20 patients (60%), showing patho-
logical [18F]FDG uptake in a median of 3 (0–19) vascular
segments. Additionally, in 8 of 20 cases (40%), the diag-
Table 2. Results of [18F]FDG-PET scans (n=30)
Baseline
scan
(n=26)
Follow-up
scan
(n=4)
PET scan under glucocorticosteroids 17 4
Diagnosis
Inflammatory large-vessel [18F]FDG
uptake
16 2
Activity
[18F]FDG uptake
Grade 0 10 2
Grade I 1 2
Grade II 12 0
Grade III 3 0
Extend of inflammatory [18F]FDG
uptake
Ascending aorta 15 2
Aortic arch 15 2
Brachiocephalic trunk 13 1
Common carotid arteries 12 0
Subclavian arteries 13 2
Axillary arteries 11 1
Descending aorta (thoracic part) 15 2
Descending aorta (abdominal part) 9 1
Iliac arteries 7 1
Femoral arteries 3 0
Popliteal arteries 2 0
Tibial/fibular arteries 2 0
Inflammatory large-vessel [18F]FDG uptake was defined as grade II
or III uptake of the thoracic aorta or any visible uptake in the
abdominal aorta or in one of the large aortic branches
Fig. 3. Sensitivity of [18F]FDG-PET in detecting large-vessel
vasculitis as a function of CRP and ESR levels (black squares,
CRP; grey squares, ESR). Curve estimates were obtained from
logistic regression models. High sensitivity for detection of large-
vessel vasculitis is achieved at high CRP and ESR levels
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Fig. 4. a The abdominal and thoracic CT scan of a 52-year-old
woman with rheumatoid arthritis, fever, night sweating and loss of
weight showed no abnormalities. b In contrast, the PET scan
revealed generalised bone marrow activation as a consequence of
chronic inflammation and demonstrated pathological [18F]FDG
uptake in the vessel wall of the aorta and its main thoracic and
abdominal branches. c, d In parallel with the distinct clinical
improvement, this uptake decreased significantly after 9 (c) and
18 months (d) of glucocorticosteroid treatment
Fig. 5. a MRI of a 45-year-old female with known Takayasu’s
arteritis revealed no vascular wall thickening in any segment, while
MRA demonstrated an aneurysmal aorta and a regular lumen of the
left subclavian artery (arrow), indicating inactive disease. b In con-
trast, the PET scan showed generalised bone marrow activation as a
consequence of chronic inflammation and demonstrated patholog-
ical [18F]FDG uptake in the wall of the left subclavian artery (arrow).
c, d This uptake decreased significantly after 9 months of gluco-
corticosteroid treatment (c). However, inflammation of the distal
subclavian artery segment was found (c, arrow), which increased
significantly after reduction of glucocorticosteroids (d, arrow)
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nosis of limited disease was upgraded to extensive disease
based on findings in respect of the aortic branches identified
as involved on [18F]FDG-PET.
Discussion
Large-vessel [18F]FDG uptake is positively correlated with
the level of acute phase reactant markers in patients with
large-vessel vasculitis. Consequently, high sensitivities are
achieved in the state of active inflammation. Additionally,
the possibility of scanning the whole body improves the
determination of the disease extent.
The ability to visualise [18F]FDG accumulation by ac-
tivated inflammatory cells makes PET a promising modal-
ity for the management of primary inflammatory diseases.
The correlation of [18F]FDG uptake with the level of bio-
chemical inflammatory markers has led to the validation
of [18F]FDG-PET for the assessment of severity of poly-
myalgia rheumatica [10]. In addition, the use of [18F]FDG-
PET in GCA or TA has recently been suggested by nu-
merous case reports [11–18] and observations in a limited
number of patients [19, 20]. Larger studies, however, are
few in number and have not yet conclusively verified the
relation between [18F]FDGuptake and severity of GCA and
TA. In 25 patients with either GCA or polymyalgia rheu-
matica, no significant correlation was found between [18F]
FDG-PET results and inflammatory markers [21]. In a
further study, 18 patients with TAwere classified into [18F]
FDG-PET-positive and -negative groups; the [18F]FDG-
PET-positive patients showed significantly higher CRP and
ESR levels than those with a negative scan [22].
In the present study we used a four-point scale (Fig. 1a)
to grade the large-vessel [18F]FDG uptake into none
(grade 0), lower than liver uptake (grade I), similar to liver
uptake (grade II) and higher than liver uptake (grade III).
This scale was proposed byMeller et al. [23], who reported
no association with their patients’ clinical or biochemical
data. In contrast, we found a highly significant correlation
between visual score and both CRP and ESR (Fig. 2);
hence, this study is the first report to validate the visual
arteritis score. With the use of this score, high inter-observer
agreement and very good intra-observer reproducibilitywere
achieved.
Nevertheless, the major advantage of the visual arteritis
score is the achievement of high specificity for active large-
vessel inflammation by excluding [18F]FDG accumulation
due to active atherosclerosis. Atherosclerotic plaques also
accumulate glucose analogues [24] andmodest large-vessel
[18F]FDG accumulation consequently occurs at the level of
the major vessels in about 50% of all PET scans [25, 26].
Accordingly, in our control group grade I vessel uptake was
frequently found in the thoracic part of the aorta. Thus, only
grade II or III uptake in the thoracic aorta and any visible
uptake in other segments should be judged to represent
active large-vessel inflammation. It is of note that grade II
or III [18F]FDG uptake regularly normalised in the follow-
up scans, which strongly argues against other than primary
inflammatory causes.
In order to draw appropriate conclusions from the [18F]
FDG-PET result, consensual data on specificity and sen-
sitivity are required; however, the currently available data
are limited and controversial. A study in 15 patients with
early untreated TA or GCA concluded that [18F]FDG-PET
identified more vascular regions than did MRA, though
sensitivity values were not provided as only PET-positive
patients were included [23]. Sensitivities of 56% and 64%,
respectively, were found for large-vessel [18F]FDG uptake
in the thorax and lower extremities in 25 patients with either
polymyalgia rheumatica or GCA [21]; no significant cor-
relation between [18F]FDG-PET results and inflammatory
markers was found. Nonetheless, in another study in 18
patients with TA, a sensitivity of 92%was reported [22]. Our
results offer an explanation for these discrepant findings.
With an overall sensitivity of 60%, we were able to show
that the sensitivity strongly depends on the present severity
of inflammation as assessed by the CRP or ESR levels
(Fig. 3). Comparedwith ESR,CRP is a better predictor of the
sensitivity of [18F]FDG-PET, and a 95.5% sensitivity can be
achieved at high CRP levels. However, several authors have
previously reported that, unlike inflammatory markers of
GCA, those of TA do not always reflect the inflammatory
activity of the disease [27]. This is also reflected by our
finding of a better correlation between biochemical inflam-
matory markers and the sensitivity of [18F]FDG-PET in
patients suffering from GCA. Nevertheless, this report is the
first to illuminate the relation between severity of inflam-
mation and sensitivity of [18F]FDG-PET. Based on our find-
ingswe suggest that, in contrast to studies that have proposed
the use of [18F]FDG-PET for the diagnosis of large-vessel
vasculitis even in the absence of elevated inflammatory
markers [22], we recommend its use mainly in active in-
flammation and, if possible, after the withdrawal of glu-
cocorticosteroid treatment.
Extracranial involvement is commonly asymptomat-
ic and most often discovered only after serious complica-
tions such as strokes, myocardial infarction, ruptured aortic
aneurysm or aortic dissection. [28–31]. However, the stan-
dard diagnostic modalities such as biopsy, angiography,
ultrasound and MRA are commonly unable to demonstrate
the full extent of vascular involvement in large-vessel
arteritis [1–5]. In contrast, [18F]FDG-PET offers the pos-
sibility of demonstrating the overall topography of large-
vessel involvement as it can visually represent the whole
body in a single image (Figs. 1b, c, 4, 5). In this study, [18F]
FDG-PET confirmed the previous diagnosis in 18 of 26
patients and found unexpected extensive involvement in
eight patients. These results are comparable to prior find-
ings and highlight themajor advantage of [18F]FDG-PET in
the work-up of patients with large-vessel vasculitis [11, 22,
23, 32, 33]. The assessment of extent, however, is limited to
extracranial vessels, as the elevated physiological glucose
metabolism in the brain obscures [18F]FDG uptake in ad-
jacent structures [34].
Nevertheless, if our results can be confirmed by other
investigators, [18F]FDG-PET may have an important role
in the non-invasive evaluation of large-vessel vasculitis
and probably allows a better understanding of the disease
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process and its distribution. The main application will be
in the evaluation of atypical presentations of large-vessel
vasculitis and in the monitoring of response to anti-in-
flammatory treatment and disease recurrence. [18F]FDG-
PET is of potential value in reducing the time to diagnosis
(by guiding the selection of the site of choice for a di-
agnostic biopsy) and in limiting the number of angiograms
performed on a patient once the diagnosis has been es-
tablished. Prospective intervention studies, however, will
be helpful in order to further clarify the role of [18F]FDG-
PET in large-vessel inflammation.
In conclusion, [18F]FDG-PET is highly effective in
assessing the activity and the extent of large-vessel vas-
culitis. A visual grading scale was validated as represent-
ing the severity of inflammation. Its use is simple and it
provides high specificity, while high sensitivity is achieved
by PET scanning during the active inflammatory phase.
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